Otsuka Holdings Co., Ltd.: Hypertension trials

The registry lists 13 Hypertension studies with Otsuka Holdings Co., Ltd. as lead sponsor. 3 are open to participants now and 4 have results posted.

Phase 3 3Phase 4 1No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The RADIANCE CED StudyRecruitingNCT07231757
• Global Paradise System US Post Approval StudyRecruitingNCT06297291
• The "Global Paradise System" RegistryRecruitingNCT05027685
• The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II HypertensionActive, not recruitingNCT03614260Not applicableResults posted
• A Study of the ReCor Medical Paradise System in Clinical HypertensionActive, not recruitingNCT02649426Not applicableResults posted
• Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular HypertensionCompletedNCT02105285Phase 3Results posted
• Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular HypertensionCompletedNCT02105272Phase 3Results posted
• OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese SubjectsCompletedNCT05583474Phase 3
• A Clinical Study of the Paradise™ Renal Denervation System in Patients With Hypertension (RADIANCE-HTN DUO)Active, not recruitingNCT05326230Not applicable
• RADIANCE Continued Access ProtocolActive, not recruitingNCT05017935Not applicable
• TrAnsCatHeter Intravascular Ultrasound Energy deliVery for rEnal Denervation (ACHIEVE)CompletedNCT01789918Not applicable
• REnAL denervatIon by ultraSound Transcatheter EmissionCompletedNCT01529372Not applicable
• A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension PatientsCompletedNCT00972426Phase 4